LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

429.72 -3.13

Buy Sell

Overview

Share price change

24h

Current

Min

428.62

Max

434.6

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	21M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+60.86% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-611M 9.9B
Previous open	432.85
Previous close	429.72

News Sentiment

By Acuity

29%

71%

67 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2026, 23:53 UTC

Hot Stocks

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 lut 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 lut 2026, 17:55 UTC

Hot Stocks

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 lut 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 lut 2026, 23:33 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 21:30 UTC

Earnings

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 lut 2026, 21:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 lut 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 lut 2026, 21:17 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 lut 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 lut 2026, 21:00 UTC

Earnings

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 lut 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 lut 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 lut 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 lut 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 lut 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 lut 2026, 19:39 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 19:38 UTC

Earnings

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 lut 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 lut 2026, 18:45 UTC

Earnings

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 lut 2026, 18:45 UTC

Market Talk

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 lut 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 17:07 UTC

Earnings

Pemex Cuts 4Q Loss As Operating Results Improve

27 lut 2026, 17:00 UTC

Market Talk

Corn Rides Oil Momentum Higher -- Market Talk

27 lut 2026, 16:31 UTC

Market Talk

Canadian Economy Shows Resilience -- Market Talk

27 lut 2026, 16:17 UTC

Market Talk

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 lut 2026, 15:49 UTC

Earnings

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

60.86% upside

12 Months Forecast

Average 694.9 USD 60.86%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

67 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.